IDH1 inhibitor-induced neutrophilic dermatosis in a patient with acute myeloid leukemia

Ivosidenib is an oral inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1). It is approved for treatment of patients with relapsed or refractory IDH1-mutated acute myeloid leukemia (AML) and patients with newly diagnosed IDH1-mutated AML who are 75 years or older or those who are ineligible to rece...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Sydney Dunn-Valadez, Srilakshmi Bathini, Carly Elston, Sravanti Rangaraju, Antonio Di Stasi, Sarah Worth, Diana Morlote, Shuko Harada, Pankit Vachhani
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Elsevier 2022-01-01
Seri Bilgileri:Cancer Treatment and Research Communications
Konular:
IDH1
Ivosidenib, Differentiation syndrome
Online Erişim:http://www.sciencedirect.com/science/article/pii/S2468294222000508
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller